The Effects of Potassium Citrate on Bone Metabolism
| Status: | Recruiting |
|---|---|
| Conditions: | Osteoporosis, Postmenopausal Syndrome, Orthopedic, Endocrine, Gastrointestinal |
| Therapuetic Areas: | Endocrinology, Gastroenterology, Rheumatology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 45 - 75 |
| Updated: | 4/2/2016 |
| Start Date: | July 2006 |
| Contact: | Kara Rysman, M.D. |
| Email: | rysmank@mskcc.org |
A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia
Skeletal buffering of chronic acid loads may contribute to a significant amount of bone loss
over time. Evidence from a few small short-term studies suggests that basic compounds,
namely potassium citrate and potassium bicarbonate may reduce bone loss and improve bone
density.
The purpose of this study is to evaluate the effects of potassium citrate on bone
metabolism. We hypothesize that administration of potassium citrate to postmenopausal women
with osteopenia will reduce bone resorption and improve bone mineral density.
Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of
fracture will be randomized to either daily potassium citrate or placebo for one year.
Primary outcomes will be markers of bone turnover, which will be measured over 12 months.
Secondary outcomes will be bone mineral density, compliance, and adverse events.
over time. Evidence from a few small short-term studies suggests that basic compounds,
namely potassium citrate and potassium bicarbonate may reduce bone loss and improve bone
density.
The purpose of this study is to evaluate the effects of potassium citrate on bone
metabolism. We hypothesize that administration of potassium citrate to postmenopausal women
with osteopenia will reduce bone resorption and improve bone mineral density.
Postmenopausal women with osteopenia (T score between -1.0 and -2.5) and no history of
fracture will be randomized to either daily potassium citrate or placebo for one year.
Primary outcomes will be markers of bone turnover, which will be measured over 12 months.
Secondary outcomes will be bone mineral density, compliance, and adverse events.
Inclusion Criteria:
- Postmenopausal women, more than 2 years post menopause
- Osteopenia, defined as a T score at the lumbar spine or total hip between -1.0 and
-2.5
- No history of prior fragility fracture
Exclusion criteria:
- Renal insufficiency
- Use of potassium sparing diuretics
- Use of potassium supplements
- Hyperkalemia
- Secondary causes of osteoporosis or metabolic bone disease
- Delayed gastric emptying
- esophageal compression, intestinal obstruction or stricture
- use of anticholinergic medication
- active urinary tract infection.
We found this trial at
1
site
Click here to add this to my saved trials
